Lowe Wealth Advisors’s Aurinia Pharmaceuticals AUPH Stock Holding History

Lowe Wealth Advisors’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-531	Closed	-$2.66K	–	314
2024 Q1	$2.66K	Hold	531	–	–	﹤0.01%	264
2023 Q4	$4.77K	Hold	531	–	–	﹤0.01%	252
2023 Q3	$4.13K	Hold	531	–	–	﹤0.01%	244
2023 Q2	$5.14K	Hold	531	–	–	﹤0.01%	266
2023 Q1	$5.82K	Hold	531	–	–	﹤0.01%	241
2022 Q4	$2.29K	Hold	531	–	–	﹤0.01%	298
2022 Q3	$4K	Hold	531	–	–	﹤0.01%	252
2022 Q2	$5K	Hold	531	–	–	﹤0.01%	229
2022 Q1	$7K	Hold	531	–	–	﹤0.01%	219
2021 Q4	$12K	Hold	531	–	–	0.01%	179
2021 Q3	$12K	Hold	531	–	–	0.01%	171
2021 Q2	$7K	Hold	531	–	–	﹤0.01%	198
2021 Q1	$7K	Hold	531	–	–	﹤0.01%	191
2020 Q4	$7K	Buy	+531	New	+$7.73K	﹤0.01%	184

Other funds holding AUPH

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Lowe Wealth Advisors's AUPH Position: Q2 2024 in Review

Lowe Wealth Advisors sold out of Aurinia Pharmaceuticals (AUPH) in Q2 2024, closing a stake of 531 shares — an estimated $2.66K sold.

Lowe Wealth Advisors first reported a position in AUPH in Q4 2020 and held it in 14 quarters. The position peaked at $12K in Q4 2021. 171 funds tracked by Wall St. Rank hold AUPH as of Q2 2024.

Lowe Wealth Advisors reported no remaining Aurinia Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Lowe Wealth Advisors sold 531 Aurinia Pharmaceuticals shares in Q2 2024, an estimated $2.66K.
Lowe Wealth Advisors first reported a position in Aurinia Pharmaceuticals in Q4 2020 and held it in 14 quarters.
Lowe Wealth Advisors's Aurinia Pharmaceuticals position peaked at $12K in Q4 2021.
171 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2024.

Based on Lowe Wealth Advisors's 13F filing for Q2 2024, filed 9 Jul 2024.